BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing - 2Embrace Effortlessness: Moderation and Cleaning up Tips
- 3Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- 46 Shades Brands For Seniors
- 56 Agreeable Earphones To Wear
- Figurine of a woman and a goose offers peek at prehistoric beliefs
- The most effective method to Recognize a Great Lab Jewel
- My Pioneering Excursion: Building a Startup
- Get To Be familiar with The Historical backdrop Of Western Medication
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- The Best 20 Photography Instagram Records to Follow
- Find the Lively Food Markets of South America
